Overview

Gender

male

Arthur A. Levin, Ph.D., is miRagen’s Executive Vice President of Research and Development. Dr. Levin is a drug development veteran having spent more than 30 years in the pharmaceutical industry, of which more than 15 years were in the area of research and development of RNA-targeting therapeutics. He is a recognized world expert on the preclinical and clinical development of oligonucleotide-based therapeutics.

Prior to joining miRagen Therapeutics, Dr. Levin was Chief Development Officer of Santaris Pharma A/S, where he led the efforts on the first microRNA-targeting therapeutic in Phase 2 clinical trials, miravirsen. Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA.Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. His expertise was instrumental in advancing more than a dozen oligonucleotide drugs from basic research to clinical development in areas such as neuromuscular diseases, infectious diseases, metabolic disorders, cardiovascular disease, and cancer. He joined Isis from Hoffmann-La Roche Inc., where he was Research Leader.

Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, New York, and a B.S. in Biology from Muhlenberg College.He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. He was the recipient of the Scala Award for Industrial Toxicology and is the author of more than 50 papers and book chapters.